<DOC>
	<DOC>NCT00599443</DOC>
	<brief_summary>A controlled, double blinded study to determine the safety and reactogenicity in healthy adults of a single dose of a trivalent cell-derived influenza vaccine administered by intramuscular injection.</brief_summary>
	<brief_title>Safety and Tolerability of a Cell-Derived Influenza Vaccine in Healthy Adults Aged ≥18 Years and ≤ 49 Years</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy female or male subjects aged ≧18 and ≦49 years Willing and able to give informed consent Influenza vaccination of laboratory confirmed influenza infection within six months of informed consent, presence of any significant medical condition, a serious adverse reaction after a previous (influenza) vaccination, underlying medical conditions for which annual influenza vaccine is recommended by the Advisory Committee on Immunization Practices (ACIP), chronic diseases requiring longterm immunosuppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Cell-derived subunit influenza vaccine</keyword>
	<keyword>Safety</keyword>
	<keyword>Reactogenicity</keyword>
</DOC>